eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinopathy, diabetic |
| Comorbidity | C0271051|macular edema |
| Sentences | 37 |
| PubMedID- 20393241 | Materials and methods: an observational case-study which included 180 type 2 diabetic patients (180 eyes) of nonproliferative diabetic retinopathy (npdr) with clinically significant macular edema (csme). |
| PubMedID- 25135585 | If the third measurement is reliable, the difference of the value from the first or second measurement is up to 3 db, and visual field abnormality is recognized in the two measurementsocular exclusion criteria (applies to the eye evaluated) 1. under treatment for glaucoma or ocular hypertension 2. either eye enucleated or eviscerated 3. cone-rod dystrophy with primarily impaired cone function 4. history of other ocular disease that can confound the outcome of the study (e.g., diabetic retinopathy, uveitis) 5. complicated by remarkable cystoid macular edema, epimacular membrane, or macular traction syndrome, diagnosed by oct 6. complicated by a nuclear cataract of moderate grade (grade 3, emery classification), an anterior subcapsular cataract, or a posterior subcapsular cataract, that may seriously affect vision 7. |
| PubMedID- 25613583 | Twenty (40 %) patients had severe non-proliferative diabetic retinopathy with mild macular edema, which is the most prevalent type among the cases group. |
| PubMedID- 23355773 | Conclusion: the results confirm the safety of intravitreal bevacizumab injection in patients with macular edema due to nonproliferative diabetic retinopathy and branch retinal vein occlusion. |
| PubMedID- 24707168 | Patients were divided into three groups: mild-moderate nonproliferative diabetic retinopathy without macular edema (npdr), mild-moderate nonproliferative diabetic retinopathy with macular edema (dme), and proliferative diabetic retinopathy (pdr). |
| PubMedID- 20642348 | Results: in type 1 diabetes patients we observed a prevalence of 36.47% of diabetic retinopathy and 5.73% with macular edema; in type 2 diabetes patients the prevalence of diabetic retinopathy was 26.11% and 6.44% with macular edema. |
| PubMedID- 22983424 | In addition, it induces vascular hyperpermeability leading, for example, to central macular edema in patients with diabetic retinopathy [33] or retinal vein occlusion [34]. |
| PubMedID- 26315560 | One-year progression of diabetic subclinical macular edema in eyes with mild nonproliferative diabetic retinopathy: location of the increase in retinal thickness. |
| PubMedID- 20936526 | Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. |
| PubMedID- 24959068 | Background: this study evaluated the effect of intravitreal injection of bevacizumab (ivb) on macular edema associated with diabetic retinopathy (dme) or branch retinal vein occlusion (brvome) using laser speckle flowgraphy. |
| PubMedID- 26106919 | We review developments in regenerative medicine (e.g., retinal prosthesis, optogenetics, cell-based therapy), diagnostics (e.g., swept source optical coherence tomography [oct], intraoperative oct, multimodal imaging), surgical innovations (e.g., chemical vitreolysis with ocriplasmin, 27-gauge vitrectomy), and pharmacological therapy of retinal vascular disease (e.g., use of ranibizumab and aflibercept in the treatment of macular edema associated with diabetic retinopathy and retinal vein occlusion). |
| PubMedID- 24349522 | In this study, we introduce choroidal area (ca; µm2) as a new parameter for analyzing choroidal quantity by edi sd-oct. ca can be used to interpret the choroidal factors that contribute to smd in non-proliferative diabetic retinopathy (npdr) patients with diabetic macular edema (dme). |
| PubMedID- 22937513 | Aim: to determine the risk factors of clinically significant macular edema (csme) in patients with non-proliferative diabetic retinopathy (npdr) in a multi-ethnics malaysian population. |
| PubMedID- 24363502 | Suggested that hba1c and total cholesterol are the two most important risk factors associated with clinically significant macular edema (csme) in patients with nonproliferative diabetic retinopathy [63] whereas zoppini et al. |
| PubMedID- 22548042 | Further studies are warranted to investigate the relationship between anemia and macular edema in patients with diabetic retinopathy. |
| PubMedID- 25923230 | In this study, therefore, we used a multiplex bead immunoassay to compare the changes in the concentrations of 27 aqueous humor cytokines in the similar severities of diabetic retinopathy patients with or without macular edema and also investigated the relationship between the levels of these factors and the severity of macular edema. |
| PubMedID- 20535227 | Background: diabetic macular edema (dme) is one of the manifestations of diabetic retinopathy leading to loss of central vision and visual acuity. |
| PubMedID- 23961505 | Fundus examination revealed bilateral severe proliferative diabetic retinopathy with macular edema and grade 2 hypertensive retinopathy. |
| PubMedID- 25097510 | That’s why most patients suffering from macular edema due to diabetic retinopathy take anti-glaucoma drugs for its management. |
| PubMedID- 25636266 | Triamcinolone acetonide (ta), as a long-term glucocorticoid, has been proved to be effective for treating macular edema associated with diabetic retinopathy (dr) and ischemic central retinal vein occlusion (crvo) [7, 8]. |
| PubMedID- 26502207 | Steroids have been extensively used to treat macular edema due to diabetic retinopathy, venous occlusive disease, ocular inflammation and, to a lesser extent, also in some cases of choroidal neovascularization. |
| PubMedID- 26501149 | Ranibizumab has been extensively investigated in clinical trials on choroidal neovascularization from wet age-related macular degeneration and pathologic myopia, as well as macular edema due to diabetic retinopathy and retinal vein occlusion. |
| PubMedID- 24707120 | Diabetic eye disease with its complications, especially diabetic retinopathy that leads to macular edema and retinal neovascularization, is the leading cause of visual dysfunction and blindness among adult working-age population in economically developed societies worldwide. |
| PubMedID- 22224029 | The fundus exam showed severe bilateral nonproliferative diabetic retinopathy, with greater macular edema in the right eye compared to the left eye. |
| PubMedID- 23204247 | Microaneurysm turnover at the macula predicts risk of development of clinically significant macular edema in persons with mild nonproliferative diabetic retinopathy. |
| PubMedID- 23807186 | Purpose: to evaluate whether intravitreal ranibizumab injection at cataract surgery prevents postoperative diabetic macular edema (pme) in patients with stable diabetic retinopathy without significant macular edema. |
| PubMedID- 22346134 | A 65-year-old male underwent intravitreal triamcinolone acetonide (ivta) injection for treating a clinically significant macular edema (csme) due to background diabetic retinopathy in his left eye. |
| PubMedID- 22279402 | Posterior segment examination [figures 1 and 2] showed mild nonproliferative diabetic retinopathy without diabetic macular edema and a normal looking optic disc od with a small cup-to-disc (cd) ratio (0.1). |
| PubMedID- 23792485 | Purpose: to evaluate the predictive value of microaneurysm (ma) formation rate concerning the development of clinically significant macular edema (csme) in patients with mild-to-moderate nonproliferative diabetic retinopathy as evaluated by an automated analysis of central field fundus 30 degrees photographs. |
| PubMedID- 24348012 | Fundus examination of the right eye showed nonproliferative diabetic retinopathy with macular edema and a swollen optic disk. |
| PubMedID- 20534920 | Two patients who had bcva < 20/200 had preexisting diabetic retinopathy with macular edema. |
| PubMedID- 20627932 | Alterations in brb occur early in the progression of diabetic retinopathy and eventually lead to macular edema, which is responsible for vision loss (2). |
| PubMedID- 25389718 | Difluprednate ophthalmic emulsion 0.05% as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy with clinically significant macular edema. |
| PubMedID- 21772983 | The purpose of this study was to evaluate the effectiveness of intravitreal ranibizumab (lucentis, genentech, south san francisco, calif, usa) combined with cataract surgery for the prevention of clinically significant macular edema (csme) in patients with diabetic retinopathy (dr). |
| PubMedID- 22667326 | Results: indications for injection included age-related macular degeneration (69.7%), diabetic macular edema (13.3%), neovascularization due to proliferative diabetic retinopathy (6.9%), and cystoid macular edema secondary to retinal vascular occlusions (10.1%). |
| PubMedID- 24978668 | Conclusion: we demonstrated a significantly reduced sensitivity in both nonproliferative diabetic retinopathy groups without diabetic macular edema compared with healthy controls; this reduction was greater in type 2 diabetic patients. |
| PubMedID- 24843311 | All the patients had proliferative diabetic retinopathy with chronic macular edema. |
Page: 1